For your consideration - Sign on letter to BD and Abbott

Dear all,

As part of the he Diagnostics Equity Consortium (DEC), O’Neill’s Global Health Policy and Politics Initiative and the Fight AIDS Coalition (FAC) are calling for individual and organizational sign-ons (endorsements) to open letters we plan on sending to diagnostics companies — Becton, Dickinson and Company (BD) and Abbott Laboratories — to bring about a course correction regarding the discontinuation of critical HIV diagnostic instruments.

These sign-on letters address the discontinuation of critical CD4 instruments that are used to monitor and measure the immune system of people living with HIV. The deadline for sign-ons is Wednesday, June 26.

As outlined in the letters, these CD4 diagnostic tests — particularly the point of care — are critical for timely detection and linkage to life-saving packages of care for advanced HIV disease /AIDS. Relying on signs and symptoms alone misses nearly half of the people with advanced HIV. With more than one AIDS death every minute, these letters aim to sustain the momentum in providing proper timely diagnosis and care for those who need it the most.

Read the letters and sign on here

Thanks for considering!


Sharonann Lynch

Associate Director, Global Health Policy & Politics Initiative | O’Neill Institute for National and Global Health Law | Georgetown University | | +1 646 824 3066